Skip to content
Search

Latest Stories

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.


He will remain in post until early July, focusing on key priorities including the medical training review for postgraduate doctors, improvements in stroke care, and commitments to ongoing inquiries.

Professor Powis was appointed national medical director of NHS England in 2018, following 12 years as medical director at the Royal Free NHS Trust.

He played a critical role in the NHS’s response to the COVID-19 pandemic, leading the health service through an unprecedented crisis, supporting frontline workers, and advising the public in numerous government briefings.

Notably, he was present when the first-ever COVID vaccine was administered to Maggie Keenan in December 2020.

During his tenure, Professor Powis has led several national reviews and overseen the development and implementation of major healthcare programmes, including national cardiovascular, respiratory, and stroke initiatives.

He also played a key role in creating the first national patient safety strategy and the rollout of medical examiners.

Reflecting on his time in the role, Professor Powis said: “It has been an immense privilege to serve as national medical director for the NHS and I am incredibly grateful to have been supported by amazing colleagues working across the NHS to boost the experiences of patients.

“I have always been exceptionally proud to work in the NHS and while stepping down from this role, I remain passionate and committed to improving the health of patients and improving the experience of staff.

Pritchard praised Professor Powis as “a dedicated public servant as well as a brilliant and kind colleague.”

“His contribution to the NHS and the country was enormous during the pandemic. I am hugely grateful – as I know our colleagues, friends and families are too – for the vital role he played leading the medical profession’s response to a once in a century health emergency,” she said.

Health Secretary Wes Streeting also acknowledged Professor Powis’s leadership, particularly in the COVID vaccine rollout and the creation of the national patient safety strategy

He stated: “Steve has provided outstanding clinical leadership to the NHS over the last eight years, including during the biggest health emergency our country has faced in modern history.

“His knowledge, professionalism, and guidance helped the NHS rise to the challenges created by the pandemic.”

Professor Powis’s departure follows Pritchard’s recent decision to stand down as NHS England’s chief executive at the end of this financial year.

Sir James Mackey, currently chief executive of Newcastle Hospitals NHS Foundation Trust and national director of Elective Recovery, will take over as transition CEO before officially assuming the role on 1 April.

Meanwhile, Dr Penny Dash was appointed as the next chair of NHS England, succeeding Richard Meddings, who is set to step down next month.

Under this new leadership, Streeting is set to publish the 10-Year Plan for Health, which aims to combine investment with reform to build an NHS fit for the future.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less